{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-020879","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.198441+00:00","generated_at":"2026-06-19T13:37:47.011112+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sesen Bio raises special dividend to $75M, extends CVR through 2027; activist investors back merger","bullets":["Special cash dividend increased to $75M ($0.36/share) from prior ~$70M; up from original $25M.","CVR period for Vicineum proceeds extended from Dec 31, 2023 to March 31, 2027.","Bradley Radoff and Michael Torok (8.7% stake) vote for merger; Torok to join Carisma board.","Special meeting to approve merger set for March 2, 2023; closing expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-020879","json":"https://secwatch.observer/filing/0001104659-23-020879.json","markdown":"https://secwatch.observer/filing/0001104659-23-020879.md","text":"https://secwatch.observer/filing/0001104659-23-020879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/0001104659-23-020879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:37:47.011112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41d1e51304e5dfb02d67c1f07936ae31f2664f49","claim":"Carisma Therapeutics Inc. amended Second Amendment to the Merger Agreement with Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics Inc. (effective 2023-02-13).","evidence_excerpt":"On February 13, 2023, Sesen Bio, Merger Sub and Carisma entered into the Second Amendment to the Merger Agreement (the “Second Amendment”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/0001104659-23-020879-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics Inc."},{"label":"Effective","value":"2023-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}